Invex Therapeutics (ASX:IXC) Cash Flow from Operations: A$-1.19 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Invex Therapeutics Cash Flow from Operations?

Invex Therapeutics ASX:IXC Cash Flow from Operations is A$-1.19 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Dec. 2025, Invex Therapeutics's Cash Receipts from Operating Activities was A$0.00 Mil. Its Cash Payments was A$-0.84 Mil. Its Dividends Paid was A$0.00 Mil. Its Dividends Received was A$0.00 Mil. Its Interest Paid was A$0.00 Mil. Its Interest Received was A$0.07 Mil. Its Taxes Refund Paid was A$0.00 Mil. And its Cash Flow from Others was A$-0.00 Mil. In all, Invex Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was A$-0.78 Mil.

Invex Therapeutics  (ASX:IXC) Cash Flow from Operations Explanation

For non-financial companies reported in direct method, cash flow from operations contains eight items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

Invex Therapeutics's cash receipts from operating activities for the six months ended in Dec. 2025 was A$0.00 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2025 was A$-0.84 Mil.

3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2025 was A$0.00 Mil.

4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2025 was A$0.00 Mil.

5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2025 was A$0.00 Mil.

6. Interest Received:
It represents interest received by the company in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2025 was A$0.07 Mil.

7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2025 was A$0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

Invex Therapeutics's cash flow from others for the six months ended in Dec. 2025 was A$-0.00 Mil.

Invex Therapeutics Cash Flow from Operations Related Terms

Invex Therapeutics Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Cash Flow from Operations Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Flow from Operations
Get a 7-Day Free Trial -1.68 -3.38 -6.87 -2.44 -0.65

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.32 -0.13 -0.24 -0.41 -0.78

Invex Therapeutics Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Invex Therapeutics's Cash Flow from Operations for the fiscal year that ended in Jun. 2025 is calculated as:

Cash Flow from Operations(A: Jun. 2025 )
=Cash Receipts from Operating Activities+Cash Payments+Dividends Paid+Dividends Received
=0.229+-1.114+0+0
+Interest Paid+Interest Received+Taxes Refund Paid+Cash Flow from Others
+0+0.232+0+1.1102230246252E-16
=-0.65

Invex Therapeutics's Cash Flow from Operations for the quarter that ended in Dec. 2025 is:

Cash Flow from Operations(Q: Dec. 2025 )
=Cash Receipts from Operating Activities+Cash Payments+Dividends Paid+Dividends Received
=0+-0.844+0+0
+Interest Paid+Interest Received+Taxes Refund Paid+Cash Flow from Others
+0+0.065+0+-0.0010000000000001
=-0.78

Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of A$-1.19 Mil mean?
Invex Therapeutics (ASX:IXC) has a Cash Flow from Operations of A$-1.19 Mil as of Dec. 2025. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Invex Therapeutics and its competitors.
Is Invex Therapeutics' Cash Flow from Operations too high?
Invex Therapeutics' current Cash Flow from Operations is A$-1.19 Mil.
How does Invex Therapeutics' Cash Flow from Operations compare to VRTX and REGN?
Invex Therapeutics' Cash Flow from Operations of A$-1.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Invex Therapeutics and its competitors. Invex Therapeutics's current Cash Flow from Operations is A$-1.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Cash Flow from Operations of A$-1.19 Mil. The current Cash Flow from Operations is A$-1.19 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Cash Flow from Operations is A$-1.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.